SCHEMBL3667795

SCHEMBL3667795

c1ccc(Cn2nnc(-c3ccc4[nH]ncc4c3)c2C2CC2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKACA P17612 7/20 1.00
CDK2 P24941 7/20 1.00
PIM1 P11309 6/20 1.00
ROCK2 O75116 6/20 1.00
AURKA O14965 5/20 1.00
CDK1 P06493 5/20 1.00
AKT1 P31749 5/20 1.00
GSK3A P49840 5/20 1.00
CDK5 Q00535 5/20 1.00
PRKCD Q05655 5/20 1.00
PRKAA1 Q13131 5/20 1.00
ROCK1 Q13464 5/20 1.00
DYRK1A Q13627 5/20 1.00
CDC42BPA Q5VT25 5/20 1.00
AURKB Q96GD4 5/20 1.00
PRKCG P05129 4/20 1.00
PRKD2 Q9BZL6 4/20 1.00
RPS6KA3 P51812 4/20 1.00
MARK3 P27448 4/20 1.00
MAPK1 P28482 4/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3668524 0.83 ROCK2 (0.70) PRKACACDK2PIM1ROCK2AURKA
SCHEMBL3666000 0.83 CDC7 (0.71) PRKACACDK2PIM1ROCK2AURKA
SCHEMBL3668504 0.82 GSK3B (0.75) PRKACACDK2PIM1ROCK2AURKA
SCHEMBL3667859 0.82 CDC7 (1.00) PRKACACDK2PIM1ROCK2AURKA
SCHEMBL27810082 0.81 GSK3B (0.71) PRKACACDK2PIM1ROCK2AURKA
SCHEMBL3670938 0.81 CDC7 (1.00) PRKACACDK2PIM1ROCK2AURKA
SCHEMBL4293399 0.80 CDC7 (0.71) PRKACACDK2PIM1ROCK2AURKA
SCHEMBL3670387 0.80 CDC7 (0.72) PRKACACDK2PIM1ROCK2AURKA
SCHEMBL3667213 0.79 GSK3B (0.79) PRKACACDK2PIM1ROCK2AURKA
SCHEMBL3665807 0.78 CDC7 (1.00) PRKACACDK2PIM1ROCK2AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US claimed
CN-101790526-A 5-heteroaryl substituted indazoles as kinase inhibitors ABBOTT GMBH & CO KG 2010-07-28 CN claimed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US claimed
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
CN-101790526-A 5-heteroaryl substituted indazoles as kinase inhibitors ABBOTT GMBH & CO KG 2010-07-28 CN disclosed
EP-2167491-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS Abbott Laboratories (US) 2010-03-31 EP disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed
WO-2008154241-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 PRKACA 178/4885CDK2 65/4885PIM1 11/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 PRKACA 178/4885CDK2 65/4885PIM1 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.